Short answer
Zimmer Biomet (ZBH) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results for quarter ended June 30, 2026.
Zimmer Biomet 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026
- Press release issued August 5, 2026
- Exhibit 99.1 contains the financial results and incorporated disclosures
Item EX-99.1 · Exhibit EX-99.1
- Q2 net sales $2.177B, up 4.8% reported and 4.0% organic constant currency, confirming broad-based growth
- Adjusted EPS $2.07 was flat year over year despite reported diluted EPS rising 33.8% to $1.03
- Technology & Data, Bone Cement and Surgical grew 21.5% organically; knees remained weak at 0.1% growth
- Full-year guidance raised: organic constant-currency revenue growth to 2.25%-3.25% and adjusted EPS to $8.47-$8.59
- Share repurchases increased to up to $1B in 2026, supporting per-share performance but reducing cash flexibility
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Zimmer Biomet 8-K filings
Get the next ZBH 8-K as it lands
Follow ZBH for push alerts, or ask the research agent what this filing means.